3Quale J,Landman D,Saurina G, et al. Manipulation of a hospital antimicrobial fomnulary to control an outbreak of vancomycin resistant enterococci. Clin Infect Dis, 1996,23 : 1020.
4National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa.
5Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372.
6Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388.
7Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364.
8Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214.
9Davin-Regi A, Bollet C, Auffray JP, et al. Use of random amplified polymorphic DNA for epidemiological typing of Strenotrophomonas maltophilia[J]. J Hosp Infect, 1996,32(1):39.
10Kanai F, Lan KH, Shiratori Y, et al. In Vivo gene therapy for alphafetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene[J]. Cancer Res, 1997,57(3) :461.
